National Cancer Institute; Notice of Closed Meetings, 75260 [06-9696]
Download as PDF
<![CDATA[
75260
Federal Register / Vol. 71, No. 240 / Thursday, December 14, 2006 / Notices
rwilkins on PROD1PC63 with NOTICES
Development Status: Animal data is
available.
Inventors: Triantafyllos Chavakis
(NCI) et al.
Publications:
(1) T Chavakis et al. Staphylococcus
aureus extracellular adherence protein
serves as anti-inflammatory by
inhibiting the recruitment of host
leukocytes. Nat Med. 2002 Jul;8(7):687–
693.
(2) C Xie et al. Suppression of
experimental autoimmune
encephalomyelitis by extracellular
adherence protein of Staphylococcus
aureus. J Exp Med. 2006 Apr
17;203(4):985–994.
Patent Status: U.S. Provisional
Application No. 60/771,884 filed 10 Feb
2006 (HHS Reference No. E–295–2005/
0–US–01).
Availability: Available for exclusive
and non-exclusive licensing.
Licensing Contact: Norbert Pontzer,
Ph.D., J.D.; 301/435–5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute
Experimental Immunology Branch is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
Novel Treatments for Autoimmune
Neuroinflammatory Diseases including
Multiple Sclerosis. Please contact Betty
Tong, Ph.D. at 301–594–4263 for more
information.
Gene Cassette for Enhancement of
Protein Production
Description of Technology: There is a
continuing market need for expression
systems that improve recombinant
protein production for disease
therapeutics or research materials. The
present invention describes a ‘‘gene
cassette’’ containing the aadA1
(aminoglycoside adenylyltransferase)
gene that increases protein expression
levels when incorporated into a
bacterial or eukaryotic host genome. In
bacterial systems, the inventors have
shown that this gene cassette induces
enhancement of protein production and
accumulation. This inducement is not
restricted by the nature of the vector,
induction system or nature of protein. In
particular, this invention has yielded 3fold upregulation of anti-HIV peptide
expression levels in a microbial
microbicide (see reference below). This
technology offers an effective
mechanism for increased product yield
that can be utilized for pharmaceutical
or biotechnological applications.
Applications: (1) Affordable gene
cassette that increases production of
recombinant or native proteins with
VerDate Aug<31>2005
17:54 Dec 13, 2006
Jkt 211000
reduced culture volume and faster
processing time; (2) Increases efficacy
and potency of cell-based therapeutics
that overexpress endogenous or
heterologous proteins.
Market: (1) Producers of protein,
peptide, or cell-based therapeutics who
would benefit from enhanced protein
expression; (2) Researchers worldwide
who utilize expression systems for
protein synthesis.
Development Status: System validated
in bacterial cells. Development
underway for use in eukaryotic
expression systems.
Inventors: Shankar Adhya and
Sudeshna Kar (NCI).
Publication: S Rao, S Hu, L McHugh,
K Lueders, K Henry, Q Zhao, RA Fekete,
S Kar, S Adhya, DH Hamer. Toward a
live microbial microbicide for HIV:
commensal bacteria secreting an HIV
fusion inhibitor peptide. Proc Natl Acad
Sci U S A. 2005 Aug 23;102(34):11993–
8. Epub 2005 Jul 22, doi 10.1073/
pnas.0504881102.
Patent Status: U.S. Provisional
Application No. 60/571,943 filed 18
May 2004 (HHS Reference No. E–261–
2003/0–US–01); PCT Application No.
PCT/US2005/17001 filed 17 May 2005,
which published as WO 2005/116222
on 08 Dec 2005 (HHS Reference No. E–
261–2003/0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Tara L. Kirby,
Ph.D.; 301/435–4426;
tarak@mail.nih.gov.
Dated: December 6, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–21301 Filed 12–13–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
Frm 00034
Fmt 4703
Sfmt 4703
Name of Committee: National Cancer
Institute Special Emphasis Panel, Molecular
Biology Special Emphasis Panel.
Date: January 29–31, 2007.
Time: 6 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
Contact Person: Michael B Small, PhD,
Scientific Review Administrator, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Blvd., Room 8127, Bethesda, MD
20892–8328, 301–402–0996,
smallm@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Clinical
Studies Special Emphasis Panel.
Date: January 31–February 2, 2007.
Time: 6 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Bethesda North Hotel and
Conference Ctr., 5701 Marinelli Road, North
Bethesda, MD 20852.
Contact Person: Majed M Hamawy, PhD,
Scientific Review Administrator, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 6116 Executive Boulevard,
Room 8133, Bethesda, MD 20852. 301–594–
5659. mh101v@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: December 6, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–9696 Filed 12–13–06; 8:45 am]
BILLING CODE 4140–01–M
National Institutes of Health
PO 00000
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 71, Number 240 (Thursday, December 14, 2006)]
[Notices]
[Page 75260]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-9696]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C. as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel, Molecular Biology Special Emphasis Panel.
Date: January 29-31, 2007.
Time: 6 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: Marriott Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Michael B Small, PhD, Scientific Review
Administrator, Research Programs Review Branch, Division of
Extramural Activities, National Cancer Institute, National
Institutes of Health, 6116 Executive Blvd., Room 8127, Bethesda, MD
20892-8328, 301-402-0996, smallm@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel, Clinical Studies Special Emphasis Panel.
Date: January 31-February 2, 2007.
Time: 6 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Marriott Bethesda North Hotel and Conference Ctr., 5701
Marinelli Road, North Bethesda, MD 20852.
Contact Person: Majed M Hamawy, PhD, Scientific Review
Administrator, Research Programs Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 6116
Executive Boulevard, Room 8133, Bethesda, MD 20852. 301-594-5659.
mh101v@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: December 6, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-9696 Filed 12-13-06; 8:45 am]
BILLING CODE 4140-01-M
